Our Story
Our Story
Scroll to explore the milestones and achievements that have made Mallinckrodt the leading pharmaceuticals company it is today.
Emil Mallinckrodt purchases a plot of land in the Bremen area of St. Louis, Missouri, which becomes the site of the first Mallinckrodt factory.
Emil's sons, Gustavo, Otto and Edward establish G. Mallinckrodt and Company, in order to supply local pharmacists with much-needed drugs. It is the only chemical company west of Philadelphia.
Becomes the leading supplier of chemicals for the emerging photography industry
Incorporates in Missouri as Mallinckrodt Chemical Works
Introduces employee healthcare benefits for the first time
Establishes its first office in New York City
Becomes the leading U.S. producer of anhydrous ammonia, an important chemical used in the refrigeration industry
Begins production of two chemicals that would go on to play a key role in the history of pain relief: morphine and codeine
Holds an exhibit at the St. Louis World’s Fair, an international event which covered industry, science and technology; a staggering 20 million people attended
Begins production of barium sulfate, a key component used in contrast media-enhanced images, for x-ray diagnoses
Perfects a new method for storing ether — the first modern anesthetic — significantly reducing impurities, and improving stability
Introduces iodeikon to the scientific community, the first x-ray contrast media used for gall bladder visualization
Purified and provided all of the uranium oxide used by the Manhattan Project (U.S.), which developed the world’s first self-sustaining nuclear chain reaction
Introduces UROKON™ SODIUM, the leading contrast media used to diagnose kidney disease
Mallinckrodt sells stock to the public for the first time
Installs the first computer system aimed at servicing Mallinckrodt customers, the RCA 301 with 40kB RAM
Acquires Van Pelt & Brown, entering into the "ethical pharmaceutical market," which includes antispasmodic and cardiovascular products
Acquires Nuclear Consultants, Inc., of Maryland Heights, Missouri, giving Mallinckrodt a foothold into the radiopharmaceutical business for nuclear medicine imaging
Mallinckrodt begins production of para-aminophenol (PAP) and N-acetyl-p-aminophenol (APAP), in response to worldwide demand for a product by the name of Tylenol®
U.S. Food and Drug Administration (FDA) approves Ultra-Technekow™ FM Technetium Tc 99m generator
Responds to the Three Mile Island nuclear reactor accident near Middletown, Pennsylvania, with the production of more than 250,000 saturated potassium iodide doses
Avon acquires Mallinckrodt
Acquired by International Minerals and Chemical Corporation which became the IMCERA Group, Inc. in 1990
Launches non-ionic x-ray contrast media in vials and pre-filled syringes
Begins contrast media production in Europe by opening a plant in Dublin, Ireland
FDA approves Octreoscan™ (kit for the preparation of indium In-III pentetreotide). IMCERA Group, Inc. becomes known as Mallinckrodt Group.
Launches the company's first generic pharmaceutical
Acquires Graham Laboratories drug dosage forms plant in Hobart, New York, as well as imaging device maker Liebel-Flarsheim, in Cincinnati, Ohio
Mallinckrodt is acquired by Tyco International
Expands the branded pharmaceuticals portfolio by acquiring five new products
Tyco Healthcare separates from Tyco International and renames itself as Covidien, an independent company
Launches the Kit for the Preparation of Technetium Tc 99m Sestamibi Injection (Tc 99m Sestamibi)
Expands pain franchise with the launch of three new pain products
Launches a line of transdermal patches for pain relief
Extends pain franchise with a co-promoted product. Acquires an immediate release branded opioid. Acquires CNS Therapeutics and its intrathecal therapy products. Receives FDA approval for the first generic of a widely prescribed attention-deficit hyperactivity disorder (ADHD) product.
Mallinckrodt Pharmaceuticals spins off from Covidien, becoming an independent, $2 billion public company that develops, manufactures, markets, and distributes specialty pharmaceutical products and diagnostic imaging agents.
Receives FDA approval for two new drugs. Acquires Cadence Pharmaceuticals and its IV analgesic product, establishing the company's hospital-focused pharmaceutical platform. Acquires Questcor Pharmaceuticals and enters the autoimmune and rare diseases space.
Acquires Ikaria, Inc., expanding into the neonatal critical care arena and adding pipeline drug focused on a rare disease. Acquires Therakos, Inc. and its immunotherapy product line, further expanding hospital platform. Divests contrast media and delivery systems business.
Acquires Stratatech Corp. and its investigational skin substitute products. Receives FDA approval for a generic version of an ADHD/narcolepsy medication. Opens global corporate headquarters in Staines-upon-Thames, United Kingdom.
Opens Specialty Brands headquarters in Bedminster, New Jersey. Opens new global Centre for Medical Device R&D in Dublin, Ireland. Acquires Infacare Pharmaceutical Corporation and its late-stage development therapy, stannsoporfin. Acquires Ocera Therapeutics and its proprietary therapy, OCR-002. Receives FDA approval for a generic version of a widely used pain medication. Divests nuclear imaging and intrathecal therapies businesses.
Acquires Sucampo Pharmaceuticals, Inc., including its commercial and development assets. Receives 2018 Manufacturing Leadership Award at its Hobart, New York site.
Completes the sale of wholly owned subsidiary BioVectra Inc. Announces positive top-line results from two pivotal phase 3 clinical trials: StrataGraft® regenerative tissue in patients with deep partial-thickness thermal burns and terlipressin CONFIRM in patients with hepatorenal syndrome type 1 (HRS-1). Announces extracorporeal photopheresis research collaboration agreement with Transimmune AG. Receives Manufacturing Leadership Award at Hobart, New York and St. Louis sites.
Receives FDA acceptance of Biologics License Application for StrataGraft® regenerative skin tissue for treatment of adults with deep partial-thickness thermal burns. Announces FDA Advisory Committee voted to recommend terlipressin for approval to treat patients with hepatorenal syndrome type 1 (HRS-1). Receives two Manufacturing Leadership Award at Hobart, New York site.
Receives FDA approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat), the first approved donor site-free alternative to autograft for deep partial-thickness burns in adults. Receives approval in Japan for the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft versus host disease (cGvHD) in adults. Announces New England Journal of Medicine (NEJM) publication of results from Phase 3 CONFIRM study of terlipressin in patients with hepatorenal syndrome type 1 (HRS-1).
Receives FDA approval for Terlivaz® (terlipressin) for injection, the first and only FDA-approved treatment for adults with hepatorenal syndrome (HRS) involving rapid reduction in kidney function.